Pfizer Inc (PFE)

$26.10 +0.24 (0.93%)
Market Cap 147.03B
Revenue (ttm) 63.63B
Net Income (ttm) 8.03B
EPS (ttm) N/A
PE Ratio 8.28
Forward PE 8.96
Profit Margin 12.62%
Debt to Equity Ratio 0.66
Volume 44,373,800
Avg Vol 49,539,543
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 58%
Beta 0.47
Analysts Sell
Price Target $28.43

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and tre...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
Micheal_Pothead
Micheal_Pothead Jan. 30 at 2:49 PM
$PFE what a typical start to the day
0 · Reply
Sunny3999
Sunny3999 Jan. 30 at 2:10 PM
$PMN fast track designation and DSMB approval and with this news $175 MILLION in the pocket ready to fly 🛫🚀 https://www.promisneurosciences.com/news-media/press-releases/detail/261/promis-neurosciences-announces-up-to-175-million-private $ABBV $CELG $JNJ $PFE
0 · Reply
doubleuptwice
doubleuptwice Jan. 30 at 2:03 PM
$PFE today will be very interesting given this weeks price action
1 · Reply
ZacksResearch
ZacksResearch Jan. 30 at 1:15 PM
$PFE set to report fourth-quarter and full-year 2025 earnings — should investors worry? Estimates for 2026 earnings have dropped from $3.15 to $2.99 per share in 60 days. Current Zacks Rank #5 (Strong Sell) with a -3.24% Earnings ESP signals potential challenges ahead. Understand the risks before investing in Pfizer 👉 https://www.zacks.com/stock/news/2825900/should-you-buy-sell-or-hold-pfizer-stock-ahead-of-q4-earnings?cid=sm-stocktwits-2-2825900-body-31117&ADID=SYND_STOCKTWITS_TWEET_2_2825900_BODY_31117
0 · Reply
JuggernautRaider
JuggernautRaider Jan. 30 at 1:14 PM
$TNXP Vertex presented at the same summit for their non-opioid analgesic. If the launch goes well, $VRTX could be one of the buyers - or someone else that needs a strong CNS product & pipeline like $GSK or $PFE ? Also wonder if Vertex is the ideal ex-US partner. Tonix can handle the US launch but Europe, Japan, China, and the other regions are a different beast 🐂
0 · Reply
ZacksResearch
ZacksResearch Jan. 30 at 12:15 PM
$PFE ahead of Q4 earnings — value trap or misunderstood setup? Strong oncology and Vyndaqel demand are bright spots, but IRA headwinds, ongoing COVID declines, and falling estimates are weighing heavily on the outlook going into the quarter. See the full Buy/Sell/Hold breakdown here 👉 https://www.zacks.com/stock/news/2825900/should-you-buy-sell-or-hold-pfizer-stock-ahead-of-q4-earnings?cid=sm-stocktwits-2-2825900-teaser-31109&ADID=SYND_STOCKTWITS_TWEET_2_2825900_TEASER_31109
0 · Reply
JBS_84
JBS_84 Jan. 30 at 7:31 AM
$PFE 27 🚀 🚀 🚀 🚀 🚀
0 · Reply
Mister_Wonderful
Mister_Wonderful Jan. 30 at 5:24 AM
$PFE 30 🚀🚀🚀🚀🚀
0 · Reply
LifeStyle_Of_The_Meek
LifeStyle_Of_The_Meek Jan. 30 at 3:51 AM
$PFE 28🚀🚀🚀🚀🚀☀️🤷‍♂️
0 · Reply
HarrisMint
HarrisMint Jan. 30 at 1:33 AM
$PFE Check in morning. Potential 1 to 2 week short play setup. Obv resistance mid 26s.
0 · Reply
Latest News on PFE
Why Dividend Stocks Are Essential For What Comes Next

Jan 30, 2026, 7:30 AM EST - 2 hours ago

Why Dividend Stocks Are Essential For What Comes Next

AM CAG EPD ET KMI LLY MPLX

Pfizer: A High-Yield Pharma At A Turning Point

Jan 29, 2026, 9:00 AM EST - 1 day ago

Pfizer: A High-Yield Pharma At A Turning Point

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

Jan 27, 2026, 4:52 PM EST - 2 days ago

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

ABBV LLY

Pfizer vs. Merck Stock And JNJ

Jan 27, 2026, 7:40 AM EST - 3 days ago

Pfizer vs. Merck Stock And JNJ

Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance

Jan 27, 2026, 6:02 AM EST - 3 days ago

Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance

Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)

Jan 23, 2026, 10:33 AM EST - 6 days ago

Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)

December Readers ID'd 9 Ideal 'Safer' Dividends In 40 Dogs

Jan 23, 2026, 9:54 AM EST - 6 days ago

December Readers ID'd 9 Ideal 'Safer' Dividends In 40 Dogs

AGNC AGNCP ARLP ECC EFC ET FBRT

Pfizer CEO Albert Bourla: U.S. drug prices are coming down

Jan 20, 2026, 12:34 PM EST - 9 days ago

Pfizer CEO Albert Bourla: U.S. drug prices are coming down

Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry

Jan 20, 2026, 12:18 PM EST - 9 days ago

Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry

NVO

Novavax enters license agreement with Pfizer for vaccine development

Jan 20, 2026, 7:11 AM EST - 10 days ago

Novavax enters license agreement with Pfizer for vaccine development

NVAX

Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits

Jan 20, 2026, 2:19 AM EST - 10 days ago

Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits

Invesco Equity And Income Fund Q4 2025 Portfolio Positioning And Performance

Jan 19, 2026, 8:10 PM EST - 10 days ago

Invesco Equity And Income Fund Q4 2025 Portfolio Positioning And Performance

BDX DD MSFT ORCL PH Q SLB

MoneyShow's Best Investment Ideas For 2026: Part 7

Jan 19, 2026, 2:20 PM EST - 10 days ago

MoneyShow's Best Investment Ideas For 2026: Part 7

PLD PLG PM QUIK RCAT

Pfizer: Rebound Has Just Started

Jan 16, 2026, 1:08 PM EST - 13 days ago

Pfizer: Rebound Has Just Started

Pfizer: The Most Intriguing Value Play Of 2026

Jan 15, 2026, 8:58 AM EST - 15 days ago

Pfizer: The Most Intriguing Value Play Of 2026

Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy

Jan 13, 2026, 6:11 AM EST - 17 days ago

Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy

Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra

Jan 12, 2026, 6:43 PM EST - 17 days ago

Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra

Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 3:16 PM EST - 17 days ago

Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

Jan 10, 2026, 10:00 AM EST - 19 days ago

Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

Healthy Returns: What to expect from pharma at the JPM conference

Jan 9, 2026, 12:57 PM EST - 20 days ago

Healthy Returns: What to expect from pharma at the JPM conference

AMGN AZN BMY LLY MRK NVO

Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity

Jan 8, 2026, 8:00 AM EST - 22 days ago

Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity

Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio

Jan 7, 2026, 2:16 PM EST - 22 days ago

Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin Papantonio

Quant Q&A With Steven Cress

Jan 7, 2026, 7:00 AM EST - 23 days ago

Quant Q&A With Steven Cress

CLS CRDO ET FIX MRK

America's new vaccine doctrine for children replaces data with dogma

Jan 6, 2026, 11:55 AM EST - 23 days ago

America's new vaccine doctrine for children replaces data with dogma

MRNA

Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens

Jan 6, 2026, 7:30 AM EST - 24 days ago

Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Jan 5, 2026, 10:00 AM EST - 24 days ago

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer 2026: The Reset Year

Jan 2, 2026, 2:52 PM EST - 27 days ago

Pfizer 2026: The Reset Year

3 ultra-high-yield stocks to consider for $300 of dividend income in 2026

Dec 31, 2025, 8:37 AM EST - 4 weeks ago

3 ultra-high-yield stocks to consider for $300 of dividend income in 2026

AGNC PFLT

Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

Dec 31, 2025, 6:08 AM EST - 4 weeks ago

Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

GSK LLY NVS SNY

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

Dec 26, 2025, 10:35 PM EST - 4 weeks ago

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

CVX KMB ABM ABT AMGN AVGO BCPC

Pfizer says patient dies after receiving hemophilia drug in trial

Dec 23, 2025, 11:24 AM EST - 5 weeks ago

Pfizer says patient dies after receiving hemophilia drug in trial

Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound

Dec 19, 2025, 11:45 AM EST - 5 weeks ago

Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound

Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 5 weeks ago

Trump to announce new drug-pricing deals later today

ABBV AMGN AZN BMY GILD LLY MRK

Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts

Dec 18, 2025, 10:00 AM EST - 6 weeks ago

Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts

Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun

Dec 18, 2025, 6:58 AM EST - 6 weeks ago

Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun

AbbVie, several other pharma companies near MFN deal with Trump, sources say

Dec 17, 2025, 4:11 PM EST - 6 weeks ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

ABBV AMGN AZN BMY LLY NVS

Pfizer Stock Can Sink More. Here Is How

Dec 17, 2025, 2:36 PM EST - 6 weeks ago

Pfizer Stock Can Sink More. Here Is How

Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back

Dec 17, 2025, 10:14 AM EST - 6 weeks ago

Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back

MRK

PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Dec 17, 2025, 6:45 AM EST - 6 weeks ago

PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript

Dec 16, 2025, 2:39 PM EST - 6 weeks ago

Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript

Pfizer falls on disappointing guidance

Dec 16, 2025, 12:33 PM EST - 6 weeks ago

Pfizer falls on disappointing guidance

Pfizer's modest 2026 outlook shows its big investments will take time to pay off

Dec 16, 2025, 10:12 AM EST - 6 weeks ago

Pfizer's modest 2026 outlook shows its big investments will take time to pay off

Here's why Pfizer is revising its revenue forecasts

Dec 16, 2025, 7:47 AM EST - 6 weeks ago

Here's why Pfizer is revising its revenue forecasts

Pfizer Stock Edges Higher on 2026 Guidance. Expect a Rough Year for Covid Vaccine Sales.

Dec 16, 2025, 7:25 AM EST - 6 weeks ago

Pfizer Stock Edges Higher on 2026 Guidance. Expect a Rough Year for Covid Vaccine Sales.

Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings

Dec 16, 2025, 7:16 AM EST - 6 weeks ago

Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings

Pfizer forecasts 2026 profit below expectations on lower COVID product sales

Dec 16, 2025, 6:54 AM EST - 6 weeks ago

Pfizer forecasts 2026 profit below expectations on lower COVID product sales

Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance

Dec 16, 2025, 6:45 AM EST - 6 weeks ago

Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance

Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million

Dec 15, 2025, 8:24 AM EST - 6 weeks ago

Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million

ADPT

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

Dec 15, 2025, 8:00 AM EST - 6 weeks ago

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

ADPT

Pfizer Declares First-Quarter 2026 Dividend

Dec 12, 2025, 12:00 PM EST - 6 weeks ago

Pfizer Declares First-Quarter 2026 Dividend

Micheal_Pothead
Micheal_Pothead Jan. 30 at 2:49 PM
$PFE what a typical start to the day
0 · Reply
Sunny3999
Sunny3999 Jan. 30 at 2:10 PM
$PMN fast track designation and DSMB approval and with this news $175 MILLION in the pocket ready to fly 🛫🚀 https://www.promisneurosciences.com/news-media/press-releases/detail/261/promis-neurosciences-announces-up-to-175-million-private $ABBV $CELG $JNJ $PFE
0 · Reply
doubleuptwice
doubleuptwice Jan. 30 at 2:03 PM
$PFE today will be very interesting given this weeks price action
1 · Reply
ZacksResearch
ZacksResearch Jan. 30 at 1:15 PM
$PFE set to report fourth-quarter and full-year 2025 earnings — should investors worry? Estimates for 2026 earnings have dropped from $3.15 to $2.99 per share in 60 days. Current Zacks Rank #5 (Strong Sell) with a -3.24% Earnings ESP signals potential challenges ahead. Understand the risks before investing in Pfizer 👉 https://www.zacks.com/stock/news/2825900/should-you-buy-sell-or-hold-pfizer-stock-ahead-of-q4-earnings?cid=sm-stocktwits-2-2825900-body-31117&ADID=SYND_STOCKTWITS_TWEET_2_2825900_BODY_31117
0 · Reply
JuggernautRaider
JuggernautRaider Jan. 30 at 1:14 PM
$TNXP Vertex presented at the same summit for their non-opioid analgesic. If the launch goes well, $VRTX could be one of the buyers - or someone else that needs a strong CNS product & pipeline like $GSK or $PFE ? Also wonder if Vertex is the ideal ex-US partner. Tonix can handle the US launch but Europe, Japan, China, and the other regions are a different beast 🐂
0 · Reply
ZacksResearch
ZacksResearch Jan. 30 at 12:15 PM
$PFE ahead of Q4 earnings — value trap or misunderstood setup? Strong oncology and Vyndaqel demand are bright spots, but IRA headwinds, ongoing COVID declines, and falling estimates are weighing heavily on the outlook going into the quarter. See the full Buy/Sell/Hold breakdown here 👉 https://www.zacks.com/stock/news/2825900/should-you-buy-sell-or-hold-pfizer-stock-ahead-of-q4-earnings?cid=sm-stocktwits-2-2825900-teaser-31109&ADID=SYND_STOCKTWITS_TWEET_2_2825900_TEASER_31109
0 · Reply
JBS_84
JBS_84 Jan. 30 at 7:31 AM
$PFE 27 🚀 🚀 🚀 🚀 🚀
0 · Reply
Mister_Wonderful
Mister_Wonderful Jan. 30 at 5:24 AM
$PFE 30 🚀🚀🚀🚀🚀
0 · Reply
LifeStyle_Of_The_Meek
LifeStyle_Of_The_Meek Jan. 30 at 3:51 AM
$PFE 28🚀🚀🚀🚀🚀☀️🤷‍♂️
0 · Reply
HarrisMint
HarrisMint Jan. 30 at 1:33 AM
$PFE Check in morning. Potential 1 to 2 week short play setup. Obv resistance mid 26s.
0 · Reply
JBS_84
JBS_84 Jan. 29 at 11:29 PM
$PFE 26.5 tomorrow.
0 · Reply
dogDazeSummer
dogDazeSummer Jan. 29 at 10:55 PM
$MLTX $IFRX The future kings of HS both looking tired of dropping. Exhausted sellers and now time to decide which BP is gonna gobble. 2 very important and completely independent MOA’s, no winner takes all with this sneaky disease. $ABBV $PFE $MRK
1 · Reply
Makingmillions192
Makingmillions192 Jan. 29 at 10:54 PM
$LEXX Dehydratech is proven to work better with small molecule peptides and that’s the future in GLP1s… Writing is on the wall for an acquisition here $LLY $PFE $NVO Who will be first?
0 · Reply
taxplanr
taxplanr Jan. 29 at 10:11 PM
AZ bill to classify mRNA as a Bioweapon introduced $BNTX $MRNA $PFE $MRK https://www.josephsansone.com/p/breaking-news-proposed-arizona-bill?utm_source=post-email-title&publication_id=1021940&post_id=184675573&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
SniperPro
SniperPro Jan. 29 at 9:10 PM
$LXRX I wish $PFE would take over Pilavapadin—they’re the best candidate to market it globally, and they have the right people ready to sell it once approved. $VTRS would be a second choice, since their salespeople are essentially a division trained by and diversified from $PFE. Also, $BMY has a stake in the development of Pilavapadin, so we might already have a partner deal on the books that just hasn’t been announced yet. Dreams do come true! Let’s hope for the best possible outcome 🚀
0 · Reply
Micheal_Pothead
Micheal_Pothead Jan. 29 at 8:56 PM
$PFE so fucking typical
0 · Reply
Micheal_Pothead
Micheal_Pothead Jan. 29 at 8:52 PM
$PFE wooo the ol faithful sell off into close
0 · Reply
EmbraceVolatility
EmbraceVolatility Jan. 29 at 7:30 PM
$PFE Obviously great ER or Metsera new pending.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jan. 29 at 6:57 PM
$SPY $AMGN $PFE $BMY $$MRK
1 · Reply
TalkMarkets
TalkMarkets Jan. 29 at 6:00 PM
Goldman Says "Good Opportunity To Buy Dip" In Obesity Drug Stocks $LLY $NVO $PFE https://talkmarkets.com/content/stocks--equities/goldman-says-good-opportunity-to-buy-dip-in-obesity-drug-stocks?post=553657
0 · Reply
Neevaka
Neevaka Jan. 29 at 5:36 PM
$CRDF check out $BHVN price action before $PFE acquired them ;)
0 · Reply
JessicaFriedman788
JessicaFriedman788 Jan. 29 at 4:45 PM
$AGNC $PFE Income focus offsets pharma stability
0 · Reply